Comparative Pharmacology
Head-to-head clinical analysis: LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL versus OGEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL versus OGEN.
LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL vs OGEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; levonorgestrel alters cervical mucus and endometrial lining to prevent fertilization and implantation.
Estrogen replacement therapy; binds to estrogen receptors, activating gene transcription leading to cell proliferation and differentiation in target tissues.
One tablet containing 0.1 mg levonorgestrel and 0.02 mg ethinyl estradiol (or 0.15 mg levonorgestrel and 0.03 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo or ethinyl estradiol 0.01 mg alone. For extended-cycle regimens, dosing may be continuous for up to 84 days.
0.75 mg orally once daily, cyclically (3 weeks on, 1 week off) for moderate to severe vasomotor symptoms associated with menopause.
None Documented
None Documented
Levonorgestrel: ~25 hours; Ethinyl estradiol: ~13 hours. Steady-state achieved within 5-7 days; clinical efficacy maintained by daily dosing.
Terminal elimination half-life of estrone is approximately 10-24 hours (mean ~14 hours); clinical context: permits once-daily dosing.
Levonorgestrel: 45% renal, 32% fecal; Ethinyl estradiol: 40% renal, 60% fecal. Both undergo enterohepatic recirculation.
Renal elimination of conjugated metabolites (estrone sulfate, estradiol glucuronide) accounts for >95% of excretion; fecal elimination is <5%.
Category D/X
Category C
Estrogen
Estrogen